Biotech

Dynavax Technologies (NASDAQ:DVAX) announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including HEPLISAV-B on its list of ACIP recommended products for use to vaccinate adults against hepatitis B. HEPLISAV-B was approved by the U.S. Food and Drug Administration (FDA) in November 2017 …

Dynavax Technologies (NASDAQ:DVAX) announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including HEPLISAV-B on its list of ACIP recommended products for use to vaccinate adults against hepatitis B. HEPLISAV-B was approved by the U.S. Food and Drug Administration (FDA) in November 2017 for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

As quoted in the press release:

“With the ACIP’s recommendation, HEPLISAV-B has cleared an important milestone needed to position Dynavax to meet our long-term commercial goals. Additionally, this recognition emphasizes the important role of HEPLISAV-B in the prevention of hepatitis B infection in adults, reinforcing our belief that our unique two-dose vaccine with demonstrated higher rates of protection versus ENGERIX-B, and a safety profile similar to three-dose vaccines, will become the new standard of care for adults,” said Eddie Gray, chief executive officer of Dynavax.

Click here to read the full press release.

MARKETS

Markets
TSX18864.90-213.74
TSXV615.29-11.05
DOW30896.47-132.84
S&P 5003807.20-11.63
NASD11112.74-65.15
ASX6700.20-63.40

COMMODITIES

Commodities
Gold1806.93-11.88
Silver20.34-0.40
Copper3.69-0.09
Palladium1939.17-22.83
Platinum904.00-15.01
Oil105.70-4.08
Heating Oil3.83-0.13
Natural Gas5.47-1.02

DOWNLOAD FREE REPORTS

×